Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SBI-115 是TGR5 (GPCR19)拮抗剂,对 TGR5 降低多囊性肝病的肝囊肿形成具有抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 483 | 现货 | ||
10 mg | ¥ 753 | 现货 | ||
25 mg | ¥ 1,498 | 现货 | ||
50 mg | ¥ 2,347 | 现货 | ||
100 mg | ¥ 3,775 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 544 | 现货 |
产品描述 | SBI-115 is an antagonist of TGR5. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 |
体内活性 | Stimulation of cholangiocytes with TLCA following by SBI-115 treatment resulted in dose-dependent (by 32–48%) inhibition of cell proliferation. |
细胞实验 | cAMP was detected by the Bridge-It cAMP designer cAMP assay. Cholangiocytes (10,000/well) were incubated with TLCA, OA, C1 and C2 (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for 15–30 min. Doses of drugs were chosen based on published data or dose ranging (SBI-115). Cell proliferation was determined by CellTiter 96 Aqueous One Solution Cell Proliferation Assay ?and by cell counting using the Cellometer Auto4 ?cell counter.?Cholangiocytes (2500 cells/well) were grown for 24–48 hours and then treated with TGR5 agonists (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for additional 24 hours.?Alterations in cell proliferation after treatment were expressed as percent change compared to un-treated cholangiocytes in which cell proliferation was considered to be equal 100%. |
分子量 | 340.78 |
分子式 | C14H13ClN2O4S |
CAS No. | 882366-16-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (440.17 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9344 mL | 14.6722 mL | 29.3444 mL | 73.3611 mL |
5 mM | 0.5869 mL | 2.9344 mL | 5.8689 mL | 14.6722 mL | |
10 mM | 0.2934 mL | 1.4672 mL | 2.9344 mL | 7.3361 mL | |
20 mM | 0.1467 mL | 0.7336 mL | 1.4672 mL | 3.6681 mL | |
50 mM | 0.0587 mL | 0.2934 mL | 0.5869 mL | 1.4672 mL | |
100 mM | 0.0293 mL | 0.1467 mL | 0.2934 mL | 0.7336 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SBI-115 882366-16-7 GPCR/G Protein GPCR19 G protein-coupled Bile Acid Receptor 1 TGR5 GPBAR1 Inhibitor G-protein coupled receptor 19 SBI 115 SBI115 inhibit inhibitor